Growth through acquisitions Instem has a history of strategic acquisitions (Strongtower, Samarind, PDS Life Sciences) and recent expansions (centrus launch), signaling a growth trajectory and integration opportunities for cross-sell of SaaS, data analytics, and workflow solutions across clinical and toxicology spaces.

Expanded clinical data Recent partnerships and product launches around digital pathology and updated nitrosamines guidance indicate demand for compliant, scalable data management and analytics across toxicology, pathology, and regulatory domains—ideal for selling enhanced data integration, reporting, and compliance tooling.

Path to automation A tech stack emphasizing automation and orchestration (Airflow, Docker, Tableau, HubSpot, Salesforce, Confluence) suggests opportunities to upsell workflow automation, data pipelines, and analytics dashboards to streamline R&D studies and regulatory workflows.

SaaS-led growth As a SaaS-based provider with mid-market revenue and 501-1000 employees, Instem is positioned to adopt scalable, subscription-based solutions across additional research services, including computational toxicology, model application, and cheminformatics, expanding ARR through cross-sell.

Global pharma alignment With competitors’ scale in the life sciences IT space and Instem’s focus on R&D efficiency, there are opportunities to target mid to large pharma and CROs for expanded regulatory-compliance platforms, digital pathology workflows, and integrated clinical study solutions.